Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Betting big on blood screens for early cancer detection

The American Society of Clinical Oncology (ASCO) just held their annual gathering in Chicago. The event coincided with some interesting new develo…


Confo Therapeutics: the next Belgian biotech star?

Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring this year, Confo Therapeutics close…

POPULAR TAGS

arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

Written by GK on in the category news with the tags , , .


In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Technology). arGEN-X creates novel therapeutic antibodies and the grant will be used to advance and commercialize the application of the NHance® technology for therapeutic antibody modifications. NHance® aims to prolong antibody circulation in the blood, which would allow for better biodistribution which leads to a reduced dosing schedule that is more convenient for patients. “We are very pleased to have received this support from IWT. As an organization, IWT has enabled the steady build of highly competitive Flemish biotechnology companies and we hope to continue this reputation with the advancement of our own novel, cutting edge research,” explains Michael Saunders, Senior Director, Targets & Programs at arGEN-X. “With the IWT grant, we aim to further confirm the benefit of antibodies equipped with NHance® by demonstrating enhanced tissue and tumour penetration with select antibody candidates.”

arGEN-X develops therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. The SIMPLE Antibody™ discovery platform generates a limitless source of high quality human antibodies, impossible to generate by any other method. These antibodies are further modified to enhance their circulation time in the body (NHance® technology), to enhance the clearance of disease targets (ABDEG™ technology) or cell-killing properties (Potelligent® technology).

Read more about: , , .

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Betting big on blood screens for early cancer detection

The American Society of Clinical Oncology (ASCO) just held their annual gathering in Chicago. The event coincided with some interesting new develo…


Confo Therapeutics: the next Belgian biotech star?

Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring this year, Confo Therapeutics close…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Turnstone Flanders.bio KU Leuven GSK XpandInnovation V-Bio Ventures Janssen Itera Life Science UGent Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.